Edgewise Therapeutics, Inc. (EWTX) Free cash flow 2020–2025
Edgewise Therapeutics, Inc. (EWTX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$144.1MFY2025 · since FY2020: -$14.8M → -$144.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$144.1M | -30.6% |
| FY2024 | -$110.3M | -12.9% |
| FY2023 | -$97.7M | -67.9% |
| FY2022 | -$58.2M | -70.2% |
| FY2021 | -$34.2M | -130.3% |
| FY2020 | -$14.8M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice